10-Q quarterly report · filed Nov 4, 2026

QuidelOrtho Corp (QDEL) Q3 2026 10-Q Quarterly Report

Short answer

QuidelOrtho Corp (QDEL) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 27, 2026. Quarterly revenue was $619M (down 11.6% year over year) with net income of −$54M.

Q3 2026 key financials · XBRL

Revenue
$619M
−11.6% YoY · −1.9% QoQ
Net income
−$54M
+92.7% YoY · +42.1% QoQ
Operating margin
-1.2%
EPS (diluted)
−$0.78
+92.8% YoY · +42.6% QoQ

Source: XBRL data from the QuidelOrtho Corp (QDEL) Q3 2026 10-Q on SEC EDGAR. USD.

QuidelOrtho Corp Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Q3 revenue $618.9M, down 12% YoY from $699.9M
  • Cost of sales margin 53.2% vs 52.1% YoY, implying gross margin 46.8% vs 47.9%
  • Best line Immunohematology $142.0M, flat YoY; worst Donor Screening $1.7M, down 88% from $14.7M
  • Cash $166.4M, down $3.4M; operating cash flow used $124.0M through nine months
  • Outlook: weaker respiratory season may persist; China pricing changes and tariffs remain headwinds, with over $80M annual savings targeted for 2027

Risk Factors

  • No material changes to risk factors since the Annual Report
  • Significant indebtedness, potentially limiting financial flexibility
  • Dependence on product development and commercialization success
  • Healthcare regulatory approvals and compliance requirements
  • Intense competition in in-vitro diagnostics markets

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other QuidelOrtho Corp quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.